期刊
MOVEMENT DISORDERS
卷 26, 期 10, 页码 1943-1947出版社
WILEY
DOI: 10.1002/mds.23793
关键词
Parkinson's disease; glial cell-derived neurotrophic factor; microspheres; neurodegeneration; 6-hydroxydopamine; tyrosine hydroxylase
资金
- UTE/Foundation for Applied Medical Research (FIMA)
- Department of Health and Education of the Government of Navarra [63/04, 17/04]
- Mapfre Medicine Foundation
- Gala Navarra Foundation
Background: Glial cell-derived neurotrophic factor is a survival factor for dopaminergic neurons and a promising candidate for the treatment of Parkinson's disease. However, the delivery issue of the protein to the brain still remains unsolved. Our aim was to investigate the effect of long-term delivery of encapsulated glial cell-derived neurotrophic factor within microspheres. Methods: A single dose of microspheres containing 2.5 mu g of glial cell-derived neurotrophic factor was implanted intrastriatally in animals 2 weeks after a 6-hydroxydopamine lesion. Results: The amphetamine test showed a complete behavioral recovery after 16 weeks of treatment, which was maintained until the end of the study (week 30). This effect was accompanied by an increase in dopaminergic striatal terminals and neuroprotection of dopaminergic neurons. Conclusions: The main achievement was the long-term neurorestoration in parkinsonian animals induced by encapsulated glial cell-derived neurotrophic factor, suggesting that microspheres may be considered as a means to deliver glial cell-derived neurotrophic factor for Parkinson's disease treatment. (C)2011 Movement Disorder Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据